Dermatophytosis Treatment Market size was valued at USD 8.85 billion in 2023 and is anticipated to reach USD 16.28 billion by the end of 2036, registering around 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of dermatophytosis treatment is assessed at USD 9.19 billion.
The growth of the dermatophytosis treatment market can be attributed to the growing population of people with weak immune systems, and rising incidences of sedentary lifestyle among people. Along with these, increasing geriatric population contributing to the high occurrence of dermatophytosis across the globe is also expected to significantly raise the demand for the treatment in the forthcoming years. According to the World Health Organization, between 2015 to 2050, the percentage of the world’s population aged 60 years and older will nearly double from 12 percent to 22 percent. In 2050, 80% of older people will be living in low- and middle-income countries.
Upsurge in the number of hospital-acquired diseases is also predicted to expand the market in the near future. Furthermore, escalating private investments for conducting research and development activities to develop novel treatment in developed nations, and rise in healthcare funding are assessed to offer profitable opportunities for dermatophytosis treatment market growth in the imminent time.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
CAGR |
4.8% |
|
Base Year Market Size (2023) |
USD 8.85 billion |
|
Forecast Year Market Size (2036) |
USD 16.28 billion |
|
Regional Scope |
|
The dermatophytosis treatment market is segmented by drug used into imidazole, econazole, clotrimazole, miconazole, ketoconazole, terbinafine, clotrimazole, corticosteroid, terbinafine, itraconazole, griseofulvin, and others, out of which, the itraconazole segment is anticipated to hold the largest share in the global market. This can be accounted to the broad antifungal spectrum and excellent effectiveness of this drug against fungal infections. Apart from these, high usage of itraconazole capsules for treating infections of the toenails is also projected to drive the segment’s growth in the future. Additionally, on the basis of end user, the clinics segment is evaluated to grab the largest share during the forecast period owing to the growing preference of patients to get treated by medical professionals operating in a specialty clinic facility.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Drug Used |
|
|
End User |
|
On the basis of geographical analysis, the dermatophytosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific industry is poised to dominate majority revenue share by 2036, propelled by increasing geriatric population, and significant improvements in the healthcare facility in the region. sIn addition, rise in disposable income and literacy levels is also projected to boost the region’s market growth in the coming years. In the ASEAN region, Singapore accounts for the highest disposable income of approximately USD 30 thousand as of 2021, whereas Malaysia’s disposable income is calculated to reach a value of close to USD 5 thousand. Moreover, the dermatophytosis treatment market in North America is anticipated to acquire the largest share during the forecast period ascribing to the availability of highly developed healthcare infrastructure, favorable reimbursement policies, and growing awareness about the benefits of early diagnosis of the disease.
April 2021- Galderma announced the publication of phase 2b trial results demonstrating the long-lasting and rapid benefits of nemolizumab.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?